Resolution of the Vi International Forum of Experts on Menopausal Hormone Therapy

Authors

  • F.A. Gafurova Tashkent Institute of Advanced Medical Education, , Uzbekistan
  • H.O. Grebennikova Institute of Reproductive Medicine; Kazakhstan Association of Sexual and Reproductive Health, Almaty, Kazakhstan
  • O.L. Gromova Bogomolets National Medical University, Kyiv, Ukraine
  • N.F. Zakharenko SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine»; clinic «Institute of Family Planning», Kyiv, Ukraine
  • O.О. Yefimenko SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine», Kyiv, Ukraine
  • N.V. Kosei SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine
  • T.F. Tatarchuk SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine»; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2025.76.8-20

Keywords:

resolution, International Forum of Experts on Menopausal Hormone Therapy, menopausal hormone therapy, endometriosis, uterine fibroids, estradiol, dydrogesterone

Abstract

On November 27, 2024, the VI International Forum of Experts on Menopausal Hormone Therapy (MHT) was held with the support of the Ukrainian Association of Gynecologists-Endocrinologists. Leading specialists from Azerbaijan, Armenia, Georgia, Kazakhstan, Uzbekistan and Ukraine took part in the event. The experts reviewed the criteria for the MHT acceptance, the features of the appointment of this therapy and its safety profile in menopausal women with endometriosis, in patients with uterine fibroids, discussed new studies on menopause and the MHT.
Regarding oncological risks, there are no restrictions on the MHT use in women with ovarian and colon cancer. In women with endometrial, cervical, lung cancer, melanoma, with BRCA1 and BRCA2 gene mutations and negative HR receptors, the benefits of MHT outweigh the risks. In case of venous thromboembolism / pulmonary embolism in the anamnesis, the absence of a progestogen component in the composition of MHT is important. In patients with migraines without aura, both estrogen and combined MHT can be used. Combined MHT with metabolically neutral dydrogesterone can be prescribed for tension headache. There are no contraindications to MHT in metabolic syndrome and diseases of the digestive system. MHT is limited in acute hepatitis and inflammatory bowel diseases, and contraindicated in liver cirrhosis.
When MHT interacts with other drugs, the effectiveness of estrogens and progestogens may be impaired. MHT can be used simultaneously with many drugs, with the exception of aromatase inhibitors, selective estrogen receptor modulators, anticonvulsants, antineoplastic drugs and immunosuppressive drugs.
A large number of women with endometriosis have symptoms of menopause and need MHT. Such therapy should be individualized taking into account the needs of the patient, it is necessary to take into account the possible recurrence of endometriosis and the risk of malignancy in menopause.
MHT can be prescribed for asymptomatic uterine fibroids in the absence of indications for surgical treatment. MHT is safest for «old» nodes of stable size. During the MHT an ultrasound monitoring of the nodes growth is needed and therapy should be discontinued if growth is detected.
The analysis of the MHT safety showed that ultra-low doses of estradiol and dydrogesterone have a beneficial effect on vasomotor symptoms and quality of life of postmenopausal women, are well tolerated without an increase in the frequency of side effects compared to placebo.

Author Biographies

F.A. Gafurova, Tashkent Institute of Advanced Medical Education,

PhD, associate professor, Department of Obstetrics, Gynecology and Perinatal Medicine;
obstetriciangynecologist,

H.O. Grebennikova, Institute of Reproductive Medicine; Kazakhstan Association of Sexual and Reproductive Health, Almaty

obstetrician-gynecologist;
executive director of the Kazakhstan Association of Sexual and Reproductive Health

O.L. Gromova, Bogomolets National Medical University, Kyiv

PhD, assistant professor, Obstetrics and Gynecology Department of Postgraduate Education

N.F. Zakharenko, SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine»; clinic «Institute of Family Planning», Kyiv

MD, professor, leading research fellow, Endocrine Gynecology Department;
head of the scientific board of the clinic

O.О. Yefimenko, SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine», Kyiv

PhD, senior researcher, Endocrine Gynecology Department

N.V. Kosei, SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, head of the Department of Reproductive Health

T.F. Tatarchuk, SI «All-Ukrainian Centre for Motherhood and Childhood of the NAMS of Ukraine»; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, corresponding member of the NAMS of Ukraine;
deputy director for research work, head of the Endocrine Gynecology Department; 
chief researcher of the Department of Reproductive Health

References

  1. Yang Z, Hu Y, Zhang J, et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017 Feb;33(2):87–92. DOI: 10.1080/09513590.2016.1248932
  2. Gompel A, Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment. Climacteric. 2018 Aug;21(4):326–32. DOI: 10.1080/13697137.2018.1476483
  3. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020 Jul 28; 324(4):369–80. DOI: 10.1001/jama. 2020.9482.
  4. Understanding the risks of breast cancer. [Internet]. British Menopause Society. 2021 Sep 10. Available from: https://thebms.org.uk/wp-content/uploads/2016/04/WHC-UnderstandingRisksofBreastCancer-MARCH2017.pdf
  5. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. DOI: 10.1136/bmj.m3873
  6. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009 Jan; 113(1):65–73. DOI: 10.1097/AOG.0b013e31818e8cd6.
  7. Franke НR, Vermes I. Di erential e ects of progestogens оn breast cancer cell. lines. Maturitas. 2003; 46 Suppl 1:S55–S58. DOI: 10.1016/j.maturitas.2003.09.019.
  8. Fournier А, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008 Jan;107(1):103–11. DOI: 10.1007/s10549-007-9523-x.
  9. Collaborative Group оп Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019 Sep 28;394(10204):1159–68. DOI: 10.1016/S0140-6736(19)31709-X
  10. Mendoza N, Ramírez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria. Maturitas. 2022;166:65–85. DOI:10.1016/j.maturitas.2022.08.008
  11. Type of Menopausal Hormone Therapy May Influence Cancer Risk. [Internet]. Healio. 2024 May 24. Available from: www. healio.com/news/hematology-oncology/20240523/type-of-menopausal-hormone-therapy-may-influence-cancer-risk
  12. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone Replacement Therapy and Endometrial Cancer Risk: A Meta-Analysis. Obstet Gynecol. 1995 Feb;85(2):304–13. DOI: 10.1016/0029-7844(94)00383-O.
  13. Academic Committee of the Korean Society of Menopause; Lee SR, Cho MK, Cho YJ, et al. The 2020 Menopausal Hormone Therapy Guidelines. J Menopausal Med. 2020 Aug;26(2):69–98. DOI: 10.6118/jmm.20000.
  14. Mitra S, Lami M S, Ghosh A, et al. Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications? Cancers. 2022 Feb 1;14(3):759. DOI: 10.3390/cancers14030759.
  15. Tian Y, Lin Y, Qu C, et al. Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk. Br J Cancer. 2024 Jun;130(10):1687–96. DOI: 10.1038/s41416-024-02638-2.
  16. Camargo C, Goto Y, Zabaleta J, et al. Sex Hormones, Hormonal Interventions, and Gastric Cancer Risk: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):20–38. DOI: 10.1158/1055-9965.EPI-11-0834
  17. Bae JM. Hormonal Replacement Therapy and Risk of Thyroid Cancer in Women: A Meta-Epidemiological Analysis of Prospective Cohort Studies. J Menopausal Med. 2021;27(3):141–5. DOI:10.6118/jmm.21023.
  18. Bezemer ID, van der Meer FJM, Eikenboom JCJ, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169:610–5. DOI: 10.1001/archinternmed.2008.589
  19. Mili FD, Hooper WC, Lally C, Austin H. The impact of co-morbid conditions on family history of venous thromboembolisms Whites and Blacks. Thromb Res 2011; 127:309–16. DOI: 10.1016/j.thromres.2010.12.012
  20. Spannaol M, Heinemann LAJ, Dominh T, et al. Comparison of incidence / risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study. Thromb J. 2005 Jul 20:3:8. DOI: 10.1186/1477-9560-3-8
  21. Tosetto A, Frezzato M, Rodeghiero F. Prevalence and risk factors ofnon- fatal venous thromboembolism in the active population of the VITA Project. J Thromb Haemost. 2003; Aug;1:1724–9. DOI: 10.1046/j.1538-7836.2003.00313.x
  22. Zöller B, Li X, Ohlsson H, et al. Age-and sex-specific seasonal variation of venous thromboembolism in patients with and without family history: a nationwide family study in Sweden. Thromb Haemost. Dec;110(6):1164–71. DOI: 10.1160/TH13-04-0320
  23. Van Vlijmen E, Wiewel-Verschueren S, Monster TBM, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016 Jul;14(7):1393–403. DOI: 10.1111/jth.13349
  24. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases, Br. Med. J. 2019 Jan 9:364:k4810. DOI: 10.1136/bmj.k4810
  25. Panay N, Ang SB, Cheshire R, et al. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. Climacteric. 2024 Oct;27(5):441–57. DOI: 10.1080/13697137.2024.2394950.
  26. Де Вільєрс Т, Татарчук ТФ, Авраменко НВ, та інші. Національний консенсус щодо ведення пацієнток у клімактерії. Репродуктивна ендокринологія. 2016. 1(27):8–25. DOI: 10.18370/2309-4117.2016.27.8-25 De Villiers T, Tatarchuk TF, Avramenko NV, et al. consensus on the management of patients in menopause. Reproductive endocrinology. 2016. 1(27):8–25. DOI: 10.18370/2309-4117.2016.27.8-25
  27. Slopien R, Wender-Ozegowska E, Rogowicz- Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas 2018;117:6–10 DOI: 10.1016/j.maturitas.2018.08.009
  28. Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women’s Health Initiative Randomized Trial. J Natl Cancer Inst. 2015 Dec 14;108(3):djv350. DOI: 10.1093/jnci/djv350.
  29. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011;12(4):1061–5.
  30. Rouen PA, Krein SL, Reame NE. Postmenopausal symptoms in female veterans with type 2 diabetes: glucose control and symptom severity. J Womens Health (Larchmt). 2015;24:496–505. DOI: 10.1089/jwh.2014.4863
  31. de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas 2016; Sep:91:153–5. DOI: 10.1016/j.maturitas.2016.06.001.
  32. Cartwright B, Robinson J, Seed PT, et al. Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density. J Clin Endocrinol Metab. 2016 Sep;101(9):3497–505. DOI: 10.1210/jc.2015-4063.
  33. Walsh BW, Schiff I, Rosner B, et al. Sacks, Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–204. DOI: 10.1056/NEJM199110243251702
  34. Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol / progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab. 1999 Jul;84(7):2402–7. DOI: 10.1210/jcem.84.7.5836
  35. Barrett-Connor E, Laakso M. 1990 Ischemic heart disease risk in postmenopausal women: effects of estrogen on glucose and insulin levels. Arteriosclerosis. 1990 Jul-Aug;10(4):531–4. DOI: 10.1161/01.atv.10.4.531
  36. Slopiena R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018 Nov:117:6–10. DOI: 10.1016/j.maturitas.2018.08.009
  37. Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020;135:82–8. DOI: 10.1016/j.maturitas.2020.03.007
  38. Wang CH, Tseng YT, Hsu HY, Tseng YT. Hormone replacement therapy is associated with reduced liver cirrhosis risk and improved survival in treatment-naive hepatitis B- and/or C- infected postmenopausal women: a nationwide long term population-based cohort study. Journal of Hepatology. 2022 Jul 21;17(7):e0271790. DOI: 10.1371/journal.pone.0271790
  39. Hales CM, Servais J, Martin CB, Kohen D. Prescription drug use among adults aged 40–79 in the United States and Canada. NCHS Data Brief. 2019 Aug:(347):1–8.
  40. Фемостон®. Instructions for medical use of the drug. [Internet]. Regulatory and directive documents of the Ministry of Health of Ukraine. [cited 2025 Mar 2]. Available from: https://mozdocs.kiev.ua/likiview. php?id=6507
  41. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009. DOI:10.1093/hropen/hoac009
  42. Jakson I, Hirschberg AL, Gidlöf SB. Endometriosis and menopause - management strategies based on clinical scenarios. Acta Obstet Gynecol Scand. 2023; 102: 1323–8. DOI:10.1111/aogs.14583.
  43. Institute for Quality and Efficiency in Health Care (IQWiG). Menopause: Learn More – Hormonal therapy for menopause. [Internet]. Informed Health Online. 2023 Jan 12. Available from: www.ncbi.nlm.nih.gov/books/NBK279309/?report=printable.
  44. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol. 2001;54:435–40. DOI: 10.1136/jcp.54.6.435
  45. Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health. 2020;26(4):181–209. DOI: 10.1177/2053369120957514
  46. Resolution of The II International Menopause Expert Forum. Reproductive endocrinology. 2021 4(60):2–10. DOI: 10.18370/2309-4117.2021.60.77-84
  47. Tanmahasamut P, Rattanachaiyanont M, Techatraisak K, et al. Menopausal hormonal therapy in surgically menopausal women with underlying endometriosis. Climacteric. Aug;25(4):388–94. DOI: 10.1080/13697137.2021.1998434.
  48. Ulin M, Ali M, Chaudhry ZT, et al. Uterine fibroids in menopause and perimenopause. Menopause. 2020 Feb;27(2):238–42. DOI: 10.1097/GME.0000000000001438
  49. Moro E, Degli Esposti E, Borghese G, et al. The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature. Medicina (Kaunas). 2019 Aug 30;55(9):549. DOI: 10.3390/medicina55090549
  50. Moravek MB, Bulun SE. Endocrinology of Uterine Fibroids: Steroid Hormones, Stem Cells, and Genetic Contribution. Curr. Opin. Obstet. Gynecol. 2015; 27:276–83. DOI: 10.1097/GCO.0000000000000185
  51. Ganesan R. Uterine smooth muscle tumour of uncertain malignant potential (STUMP): Where are we now? Case Rep Womens Health. 2020; 26:e00176. DOI: 10.1016/j.crwh.2020.e00176
  52. Chang IJ, Hong GY, Oh YL, et al. Effects of Menopausal Hormone Therapy on Uterine Myoma in Menopausal Women. J. Menopausal Med. 2013;19:123–9. DOI: 10.6118/jmm.2013.19.3.123
  53. Botía CP, Camarasa SC, Baixauli FR, Sanchez A C. Uterine Fibroids: Understanding their Origins to Better Understand their Future Treatments. [Internet]. Journal of Tumor Research. 2017, 3:3. Available from: https://www. longdom.org/open-access-pdfs/uterine-fibroids-review-understanding-their-origins-to-better-understand-their-future-treatments.pdf
  54. Yang CH, Lee JN, Hsu SC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas. 2002 Sep 30;43(1):35–9. DOI: 10.1016/s0378-5122(02)00159-7.
  55. Stewart E A, Laughlin-Tommaso S K, Catherino W H. Uterine fibroids. Nat Rev Dis Primers. 2016 Jun 23:2:16043. DOI: 10.1038/nrdp.2016.43.
  56. Tatarchuk T, Stevenson JC, Yu Q, et al. Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis. Gynecol Endocrinol. 2024;40(1):2375577. DOI: 10.1080/09513590.2024.2375577.

Downloads

Published

2025-03-31

How to Cite

Gafurova, F., Grebennikova, H., Gromova, O., Zakharenko, N., Yefimenko, O., Kosei, N., & Tatarchuk, T. (2025). Resolution of the Vi International Forum of Experts on Menopausal Hormone Therapy. REPRODUCTIVE ENDOCRINOLOGY, (76), 8–20. https://doi.org/10.18370/2309-4117.2025.76.8-20

Issue

No. 76 (2025)

Section

Management of menopause

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.